

FAQs

Catalogue of Requirements for the Neuro-oncology Centres In Oncology Centres

Chairs of the Certification Committee: Prof. Dr. Uwe Schlegel, Prof. Dr. W. Stummer

Within the framework of the certification procedure, questions regularly crop up which require an explanation of the Technical and Medical Requirements. This document contains answers to the questions which the centres can refer to when implementing, and the experts can refer to when assessing the Technical and Medical Requirements.

Version FAQ and Catalogue of Requirements (CR)

Version status FAQs: 31 August 2022

The FAQs in this document refer to the following documents which are now in force:

| | | |
|---------------------------------|--------------|------------|
| Catalogue of Requirements Neuro | Version G1 | 31.08.2022 |
| Indicator Sheet Neuro | Version G1.1 | 31.08.2022 |

Overview of FAQs

Catalogue of Requirements

| Section CR | Requirements | | Last update |
|---|------------------|---|-------------|
| 1.1 Structure of the network | 1.1.2 | Main cooperation partners | 14.07.2016 |
| 1.2 Interdisciplinary cooperation | 1.2.2 | Interdisciplinary pre-intervention tumour board | 29.07.2020 |
| | 1.2.3 | Interdisciplinary tumour board | 19.07.2018 |
| 1.4 Psycho-oncology | 1.4.4 | Neuropsychology | 14.07.2016 |
| 1.6 Patient involvement | --- | Self-help groups | 29.07.2020 |
| 1.7 Study management | 1.7.4 | Proportion study patients | 14.07.2016 |
| 5.2 Cross-organ surgical therapy | 5.2.3a 5.2.3b | Surgical primary cases Biopsies | 31.08.2022 |
| 8 Pathology | 8.6.1 | Assessment frozen sections / specimens | 19.07.2018 |
| 10 Tumour Documentation/ Outcome Quality | 10.2 | Kaplan-Meier-curves | 19.07.2018 |
| | | Follow-up | 19.07.2018 |

Indicator Sheet

| Indicator | | Last update |
|-----------|---|-------------|
| --- | Basic Data | 31.08.2022 |
| 2a | Interdisciplinary case reviews (tumour board) | 14.07.2016 |
| 2b | Pretherapeutic tumour board | 31.08.2022 |
| 3 | Psycho-oncological distress screening | 31.08.2022 |
| 4 | Counselling social services | 19.07.2018 |
| 7a | Revision surgeries | 14.07.2016 |

FAQs - Catalogue of Requirements - Neuro

1.1 Structure of the network

| Section | Requirements | | |
|---------|--|--|--|
| 1.1.2 | <p>Cooperation agreements Main cooperation partners Neurosurgery, neurology, neuroradiology, neuropathology, radio-oncology, haematology and oncology and medicinal oncology</p> <p>Cooperation partners In addition to the cooperation partners mentioned in the Catalogue of Requirements, cooperation agreements are to be entered into with: pathology, neuropsychology, psychiatry, paediatric haematology and oncology, occupational therapy, ophthalmology, endocrinology and speech therapy.</p> | <p><u>FAQ (14.07.2016)</u> Neurology and neurosurgery must be located at one site.</p> | |

1.2 Interdisciplinary cooperation

| Section | Requirements | | |
|---------|---|--|--|
| 1.2.2 | <p>Interdisciplinary pre-intervention tumour board</p> <p>Cycle A tumour board must be staged at least once a week.</p> <p>Participants: Neurosurgeon, neurologist, neuroradiologist, neuropathologist, radiotherapist, internal oncologist**. Related to the indication, e.g. in the case of cerebral metastases the presenting specialties are to be invited to the tumour conference.</p> <p>**Haematologist/oncologist If the haematologist/oncologist is unable to attend the conference, he/she may be represented by the neuro-oncologist responsible for chemotherapy (qualification in line with section 6.2).</p> | <p><u>FAQ (29.07.2020)</u> In principle, the participation of a haemato-oncologist is required. In exceptional cases, this can be represented by the qualified neurologist or neurosurgeon responsible for chemotherapy.</p> | |

| | | | |
|-------|---|---|--|
| 1.2.3 | <p>Interdisciplinary tumour board All primary case patients should be presented in the interdisciplinary tumour conference: Elective patients: pre-intervention, emergency patients: at least post-intervention (Patient can only be taken into account 1x for the numerator).</p> <p>Scale of the discussed primary cases $\geq 95\%$</p> | <p><u>FAQ (19.07.2018)</u> All primary cases should be presented at the interdisciplinary tumour conference. Whenever possible, all patients should be presented pre-interventionally. However, the following must be ensured as a minimum: elective patients pre-interventionally and emergency patients (at least) post-interventionally. (at least) post-intervention. Each patient can only be considered once for the numerator.</p> | |
|-------|---|---|--|

1.4 Psycho-oncology

| Section | Requirements | | |
|---------|--|---|--|
| 1.4.4 | <p>Neuropsychology</p> <ul style="list-style-type: none"> • 1 psychologist with the additional designation Clinical Neuropsychologist (GNP) is available to the Centre (if necessary via cooperation). • Cooperation must be presented by way of documented cases during the assessment period. • The following processes are to be described with details of responsibilities: <ul style="list-style-type: none"> • patient presentation criteria; • communication within the Centre; • participation in events, quality circles, tumour board and similar events of the Centre. | <p><u>FAQ (31.08.2022)</u> Does the neuro-oncology centre have to have a psychologist who is also a neuropsychologist?</p> <p>Answer: No, 1 psychologist must have the additional training in clinical neuropsychology GNP. In addition, other psychologists without the additional training may work for the NOC (Neuro-oncology Centres).</p> | |

1.6 Patient involvement

| Section | Requirements | | |
|---------|------------------|---|--|
| 1.6 | Self-help groups | <p><u>FAQ (29.07.2020)</u> If there are no regional brain tumour self-help groups, supraregional self-help initiatives (e.g. Deutsche Hirntumorhilfe) should also be considered and included.</p> | |

1.7 Study management

| Section | Requirements | | |
|---------|--|---|--|
| 1.7.4 | <p>Proportion study patients</p> <p>1. Initial certification: At the time of initial certification ≥ 1 patient must have been included in studies.</p> <p>2. after 1 year: at least 5% of malignant primary case number (ICD C70-72, C75.1-3)</p> <p>Only the inclusion of patients in studies with an ethical vote counts as study participation (non-interventional/diagnostic studies and prevention studies are also recognised, sole biobank collections are excluded).</p> <p>All study patients can be taken into account when calculating the study rate (share study patients based on the Centre's primary case number). General preconditions for the definition of the study quota:</p> <ul style="list-style-type: none"> • Patients can be counted 1x per study, time: Date of patient's informed consent. • Patients in the palliative and adjuvant situation can be counted, no limitations regarding stage of disease. • Patients who are taking part in several studies simultaneously can be counted several times. <p>The study rate can also be achieved in cooperation with other active units.</p> | <p><u>FAQ (14.07.2016)</u></p> <p>Patients of centre A can participate in studies in another clinic/centre and be counted for the study quota of centre A. Patients can only be counted for study quota of centre A, no double counting.</p> <p><u>FAQ (31.08.2022)</u></p> <p>Can negatively screened study patients be counted?</p> <p>Patients who have signed a informed consent form for screening for study participation can be counted for the numerator of the respective study indicator, even if the results of screening examinations carried out with special diagnostics (no routine diagnostics) do not allow the patient to participate in the study.</p> | |

| | | | |
|-------|---|--|--|
| 5.2.3 | <p>5.2.3a Surgical primary cases</p> <p>At least 60 primary cases (Definition see CR 1.2.1) are operated every year. All surgeries (primary cases and recurrences) are to be performed under the supervision of the named surgeon (as 1. or 2. surgeon or along the lines of documented supervision).</p> <p>Definition surgical therapy German procedure classification (OPS): 5-015.0; 5-015.1; 5-015.3; 5-015.4; 5-016.0; 5-016.2; 5-016.4; 5-016.6; 5-017.1, 5-035, 5-075</p> <p>5.2.3b Biopsies: Recording biopsies for primary cases: German procedure classification (OPS): 1-510.; 1-511; -1-512.; 1-514; 1-515</p> | <p><u>FAQ (31.08.2022)</u></p> <p>The OPS code 5-016.0 does not stand for a specific procedure, but represents a kind of heading/trunk. Should a 0, 1, 2 or 3 be added in the eighth position?</p> <p>Answer: Subsumed codes are included in each case, this also applies to chap. 5.2.3</p> | |
| 5.2.4 | Qualification surgeons | | |

| | | | |
|--|--|--|--|
| | <ul style="list-style-type: none"> Per surgeon evidence of at least 25 open neuro-oncological operations/year (as 1st or 2nd surgeon as part of training of new surgeons). The special qualification of surgeons is documented via curricula. <p>OPS classification: 5-015.0; 5-015.1; 5-015.3; 5-015.4; 5-016.0; 5-016.2; 5-016.4; 5-016.6; 5-017.1; 5-035; 5-075</p> | | |
|--|--|--|--|

8 (Neuro-) pathology

| Section | Requirements | | |
|---------|--|--|--|
| 8.6.1 | <p>Assessment frozen sections / specimens</p> <ul style="list-style-type: none"> All frozen sections / sections are to be diagnosed by neuropathologists (as a rule on site, possibly via cooperation; cooperations > 45km are to be justified). In exceptional cases the cutting of the frozen section may be undertaken by pathologists on site. In these cases, the telemedical microscopic assessment of the frozen sections must be done by the neuropathology specialist. | <p><u>FAQ (19.07.2018)</u></p> <p>All preparations and frozen sections must be evaluated by a specialist in neuropathology. As a rule, this specialist should be on site at the centre.</p> <p>- In justified individual cases, a distance of >45 km between the centre and neuropathology is permissible.</p> <p>- If no neuropathologist is available on site, the pathology specialist may, in exceptional cases, carry out the cutting of the frozen section preparation and the histological assessment may be carried out by the neuropathologist via telemedicine.</p> | |

10 Tumordokumentation / Ergebnisqualität

| Section | Requirements | | |
|---------|--------------|--|--|
| | | | |

| | | | |
|------|--|---|--|
| 10.2 | <p>Tumour documentation system</p> <ul style="list-style-type: none"> • Tumour documentation, which contains the patient data for a minimum period of 3 months, must be in place at the time of initial certification. • The patients with neuro-oncological tumours must be recorded in <u>one</u> tumour documentation system. <p>Name of the tumour documentation system in a cancer registry and/or Centre</p> <p>A data set in line with the Uniform Oncological Basic Data Set (<i>Einheitlicher Onkologischer Basisdatensatz</i>) and its modules of the Working Group of German Tumour Centres (<i>Arbeitsgemeinschaft Deutscher Tumorzentren - ADT</i>) and the Association of Population-based Cancer Registries in Germany (<i>Gesellschaft der epidemiologischen Krebsregister in Deutschland - GEKID</i>) must be used.</p> <p>The Centre must ensure that the data transfer to the competent cancer registry is done in a timely manner. Any existing federal state laws for notification deadlines are to be complied with.</p> | <p><u>FAQ (19.07.2018)</u></p> <p>Do Kaplan-Meier curves have to be drawn up by the centre with the patients of the neuro-oncology centre?</p> <p>Answer: The presentation of Kaplan-Meier curves is not obligatory for the NOZ. The presentation of the clinical course, i.e. the quality of outcome, is the task of the cancer registries.</p> <p><u>FAQ (19.07.2018)</u></p> <p>Does the centre have to collect follow-up data for the patients of the neuro-oncology centre?</p> <p>Answer: No, follow-up data do not have to be collected. The presentation of the clinical course, i.e. the quality of outcome, is the task of the cancer registries.</p> | |
|------|--|---|--|

FAQs - Indicator Sheet Neuro

| | | | | |
|------------|---|---|---|---|
| Basic data | | <p><u>FAQ (14.07.2016):</u> Peripheral neuro-tumours, like spinal tumours, cannot be coded. Instead, cavernomas, for example, can be coded under the guise of haemangioblastomas.</p> <p>Answer: No coverage of peripheral neuro-TM, Cavernomas may also not be counted.</p> | | |
| | | <p><u>FAQ (14.07.2016):</u> It seems implausible that the same patient with first e.g. astrocytoma WHO grade II or III and then glioblastoma cannot be recorded twice as a primary case.</p> <p>Answer: In principle, counting according to the procedural instruction 1x as primary case, in the same year additionally 1x with first diagnosis recurrence/ metastasis countable, otherwise 1x annually with recurrence/ metastasis.</p> | | |
| | | <p><u>FAQ (26.06.2019):</u> Some patients have been diagnosed with an intracranially located epidermoid (histologically confirmed). Can these tumours be counted as primary cases?</p> <p>Answer: Intracranial epidermoid cysts may not be counted as primary cases for the Neuro-oncology Centre.</p> | | |
| 2a | Interdisciplinary case reviews (tumour board) | Numerator | Primary cases of the denominator (elective patients:pre-intervention, emergency patients: post-intervention) who were presented in the tumour board | <p><u>FAQ (14.07.2016):</u> Each patient (= elective and emergency) can only be counted once for the counter, regardless of the number of presentations.</p> |
| | | Denominator | Primary cases (= Indicator 1a) | |
| | | Target value | ≥ 95% | |
| 2b | Pretherapeutic tumour board | Numerator | Primary cases of the denominator that were presented in the tumour board before the intervention | <p><u>FAQ (31.08.2022)</u> A biopsy already counts as an intervention. Does the patient have to be presented before a biopsy is taken?</p> <p>Answer: Yes, "pre-interventional" also means a presentation before a possible biopsy.</p> |
| | | Denominator | Primary cases (= Indicator 1a) | |
| | | Target value | No target value | |
| 3 | Psycho-oncological distress screening | Numerator | Patients of the denominator who received psycho-oncological distress screening | <p><u>FAQ (14.07.2016):</u> Psycho-oncological care in all inpatient and outpatient departments should be counted for the numerator (e.g. psycho-oncological care in radiotherapy).</p> |

| | | | | |
|----|-----------------------------|--------------|--|--|
| | | Denominator | Primary cases (= Indicator 1a) and patients with recurrence / progress (= Indicator 1b) | <p><u>FAQ (19.07.2018):</u> Per patient, one recurrence/progression of the primary tumour per calendar year can be counted for the denominator.</p> |
| | | Target value | ≥ 65% | |
| 4 | Counselling social services | Numerator | Patients of the denominator who received counselling by social services in an inpatient or outpatient setting | <p><u>FAQ (19.07.2018)</u> For each patient, 1 recurrence/progression of the primary tumour per calendar year can be counted for the denominator.</p> |
| | | Denominator | Primary cases (= Indicator 1a) and patients with recurrence / progress (= Indicator 1b) | |
| | | Target value | No target value | |
| 7a | Revision surgeries | Numerator | Primary cases of the denominator with revision surgeries as a consequence of postsurgical complications within 30d of surger | <p><u>FAQ (14.07.2016)</u> Revision operations are defined by the documentation of an OPS code.</p> <p><u>FAQ (14.07.2016)</u> Post-operative resections should not be counted for the numerator. However, postoperative CSF fistulas are counted.</p> |
| | | Denominator | Surgical primary cases (= indicator 6a) | |
| | | Target value | ≤ 10% | |

FAQ's - Datenblatt Neuro

| | | | | |
|----|-----------------------------|--------------|--|--|
| 4 | Counselling social services | Numerator | Patients of the denominator who received counselling by social services in an inpatient or outpatient setting | <u>FAQ (19.07.2018):</u> For each patient, 1 recurrence/progression of the primary tumour per calendar year can be counted for the denominator. |
| | | Dominator | Primary cases (= Indicator 1a) and patients with recurrence / progress (= Indicator 1b) | |
| | | Target value | No target value | |
| 7a | Revision surgeries | Numerator | Primary cases of the denominator with revision surgeries as a consequence of post-surgical complications within 30d of surgery | <u>FAQ (14.07.2016):</u> Revision operations are defined by the documentation of an OPS code (German procedure classification) <u>FAQ (14.07.2016):</u> Post-operative resections should not be counted for the numerator. However, postoperative cerebrospinal fluid fistulas are counted. |
| | | Denominator | Surgical primary cases (= indicator 6a) | |
| | | Target value | No target value | |